UK markets closed

Establishment Labs Holdings Inc (3E0.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
52.50+2.50 (+5.00%)
At close: 08:13AM CEST
Full screen
Previous close50.00
Open52.50
Bid52.00 x N/A
Ask52.50 x N/A
Day's range52.50 - 52.50
52-week range19.90 - 65.50
VolumeN/A
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Establishment Labs Reports First Quarter 2024 Financial Results

    NEW YORK, May 08, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024.

  • Business Wire

    Establishment Labs Notes Presentation of 4-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2024

    NEW YORK, May 02, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include four-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the result

  • Business Wire

    Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

    NEW YORK, May 01, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in